
Although use of zzso factor zzso is widespread and guidelines for use have been zzso actual practice patterns of medical zzso are zzso The purpose of this study was to collect these data using an zzso computerized clinical information zzso 

Data were collected on patients at 10 community-based zzso zzso Information regarding zzso use was captured at the time of prescribing through a computerized clinical support tool and stored in a data zzso and an analysis was carried out zzso 

A total of zzso cancer regimens administered to zzso patients were evaluated for growth factor zzso Overall, zzso were used in zzso of regimens, with breast, lymphoma, zzso and zzso being the most common zzso for which zzso were zzso In zzso of regimens, zzso was initiated during cycle 1, with an average duration of 1 week, and was used in two or three cycles per zzso zzso zzso is rarely followed by zzso zzso zzso zzso factor zzso is associated with fewer dose adjustments, delays, and zzso when compared with zzso colony stimulating factor zzso There is wide variation among zzso in zzso use, and several substantial differences were noted between the prescribing behavior of American Society of Clinical Oncology zzso zzso zzso and actual clinical practice, as captured by the computerized clinical information zzso 

zzso clinical information systems can collect detailed information regarding practice patterns of medical zzso zzso physician practice survey data do not accurately reflect actual practice patterns and must be interpreted with zzso zzso zzso from zzso growth factor guidelines remain, and zzso use of zzso demonstrates wide zzso There may be important clinical differences between zzso and zzso but definitive phase III trials are needed for zzso 

